GlassScriptPhysician profile
Miranda P Frith
NPI 1538274238
$3,135.08
in general payments reported to CMS, 2019-2025
22 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 90% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $376 · 2023: $717 · 2024: $1,041 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.49 |
| Education | $269.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.14 | 2022-2025 | |
| Janssen Biotech, INC. | $521.73 | 2022-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $263.89 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $259.73 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $197.14 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $170.86 | 2022-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $135.55 | 2023-2024 | Sotyktu |
| Ucb, INC. | $134.52 | 2023-2025 | Bimzelx, Cimzia |
| Organogenesis INC. | $126.85 | 2023-2025 | Affinity, Via Matrix, Puraply |
| Pfizer INC. | $96.10 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Amgen INC. | $82.28 | 2022-2025 | Otezla, Actimmune, Otezla |
| Leo Pharma INC. | $73.11 | 2023-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $65.71 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.66 | 2023 | Spevigo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $43.64 | 2023 | Seysara |
| Galderma Laboratories, L.P. | $34.52 | 2025 | Nemluvio |
| Incyte Corporation | $29.24 | 2022-2023 | Opzelura |
| Biofrontera INC. | $29.00 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Scientific Affairs, LLC | $27.13 | 2022 | |
| Arcutis Biotherapeutics, INC. | $17.22 | 2023 | |
| Convatec INC. | $14.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Frith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.